Clinical trials

Only want trials near your city that fit you? Get alerts

Disease

Country

Status

Phase

Reset

595 trials

NCT05853965
Recruiting
Combination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed and Refractory t(11;14) Multiple Myeloma
Phase 1/2 · Germany · 7 sites
Registry update: 18 May 2026
NCT06052826
Recruiting
Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART Study
Phase 2 · United States · 4 sites
Registry update: 22 Oct 2026
NCT05892393
Recruiting
Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma
Phase 1 · United States · 1 site
Registry update: 16 Sept 2026
NCT06252792
Recruiting
Dara-PD in the Treatment of Patients With First Relapse of Multiple Myeloma
Not applicable · China · 1 site
Registry update: 3 Apr 2026
NCT05714839
Recruiting
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
Phase 1/2 · Argentina, Australia, Brazil, China, Germany, Finland, United Kingdom, Greece, Israel, Italy, Japan, South Korea, Poland, Sweden, Taiwan, United States, South Africa · 59 sites
Registry update: 19 Aug 2026
NCT05970198
Recruiting
Helical Tomotherapy in Multiple Myeloma
Not applicable · China · 1 site
Registry update: 1 Aug 2023
NCT05636787
Recruiting
Clinical Trial Investigating the Chemotherapeutic Compound Treosulfan (Trecondi® Ideogen) in Myeloma Patients
Phase 2 · Switzerland · 1 site
Registry update: 8 Jul 2024
2024-519194-19-00
Recruiting
Phase 1/2 multicenter, open-label, dose-escalation study of IDP-121 in patients with relapsed/refractory hematologic malignancies (CASSANDRA)
Phase 1/2 · Spain · 12 sites
Registry update: 26 Jun 2026
NCT05908409
Recruiting
A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies
Phase 1/2 · Spain · 11 sites
Registry update: 1 May 2025
NCT07403630
Recruiting
INTEGRATIVE "MULTI-OMICS" AND FUNCTIONAL PLATFORM FOR THE COMPLETE DIAGNOSTIC CHARACTERIZATION OF TUMORS: THE ITALIAN TUMOR CHEMOGENOMIC PROFILER (IT-TCP)
Not applicable · Italy · 2 sites
Registry update: 17 Feb 2026
NCT05992532
Recruiting
GammaGA: Prevalence of Acid Sphingomyelinase Deficiency Disease (ASMD) and Gaucher Disease in Patients With Monoclonal Gammopathies and/or Multiple Myeloma
Not applicable · Spain · 23 sites
Registry update: 11 Feb 2026
NCT05789303
Recruiting
Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma
Phase 2 · United States · 2 sites
Registry update: 23 Sept 2026
NCT05841550
Recruiting
The TG01 Study With TG01/QS-21 Vaccine in Patients With High-risk Smouldering Multiple Myeloma and Multiple Myeloma
Phase 1/2 · Norway · 1 site
Registry update: 5 Aug 2025
NCT05405387
Recruiting
Impact of Budesonide on Incidence of ≥ Gr2 Diarrhea in Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplant
Phase 2 · United States · 1 site
Registry update: 5 Jun 2026
NCT06383143
Recruiting
Promoting Diagnosis and Management of AL in Italy (ProDigALIty)
Not applicable · Italy · 4 sites
Registry update: 16 Apr 2026
NCT06236373
Recruiting
The Unmet Needs of Cancer Survivors in Ausl IRCCS Reggio Emilia
Not applicable · Italy · 1 site
Registry update: 9 Dec 2024
NCT05759793
Recruiting
A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
Phase 1 · China · 1 site
Registry update: 20 May 2025
NCT05530421
Recruiting
Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma
Phase 2 · United States · 3 sites
Registry update: 23 Feb 2026
NCT05650632
Recruiting
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
Phase 1 · Canada, Denmark, Spain, France, United Kingdom, Israel, United States · 44 sites
Registry update: 10 Nov 2026
Conflicting statuses (updated in the registry within the last month)
NCT05768178
Recruiting
DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.
Phase 2/3 · United Kingdom · 16 sites
Registry update: 24 Nov 2025

Ordered by registry start date. Freshness and sponsorship never change the order.